Outlook on the World's Skin Cancer Diagnostics and Therapeutics Market, 2019-2024: Growth, Trends & Projections - ResearchAndMarkets.com

DUBLIN--()--The "Skin Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

The global skin cancer diagnostics and therapeutics market are expected to witness a CAGR of 10.4% over the forecast period.

Certain factors driving the market growth include increasing incidence of skin cancer, extensive R&D pipelines, and rising awareness about skin cancer.

Skin cancer is the most common form of cancer. Even though most types of skin cancers are preventable, its incidence is increasing. People can recognize changes in their skin during the early stages of the disease. The risk factors include sunlight, sunlamps and tanning booths, certain medical conditions, or medicines. The UV radiation changes the genetic material (DNA) in cells and is, therefore, the main cause of skin cancer.

According to the American Cancer Society, exposure to the sun is the most preventable risk factor for all skin cancers. The rate of new melanoma cases among both men and women has been increasing at 1.7% and 1.4% per year respectively, as per the data of Federal Centers for Disease Control and Prevention (CDC). Thus, the increasing prevalence of skin cancer is augmenting the growth of the market studied.

However, a common side effect of radiation therapy is skin irritation in the area of the body that is being treated. The skin reaction can range from mild redness and dryness (similar to a sunburn) to severe peeling (desquamation) of the skin in some patients. The majority of skin reactions to radiation therapy go away a few weeks after the treatment is completed. In some cases, the treated skin will remain slightly darker than it was before and may continue to be more sensitive to sun exposure.

About two to three weeks after first radiation treatment, redness is noticed and irritation is similar to a sunburn. The skin may be itchy, dry, red, or sore. There are also long-term side effects, like changes in skin color, lung problems, and others, which act as major restraints for the growth of the market studied.

Key Market Trends

Non-melanoma is expected to hold a Significant Market Share in the Disease Type

According to the ASCO (American Society of Clinical Oncology), it is estimated that more than 3 million people in the United States are diagnosed with non-melanoma skin cancer each year. Basal cell carcinoma is far more common than squamous cell carcinoma. About 80% of non-melanoma skin cancer is basal cell carcinoma. Similarly, the CCS (Canadian Cancer Society) states that non-melanoma skin cancer is the most common cancer diagnosed among Canadians. It makes up at least 40% of all new cancer cases in Canada.

Furthermore, it has been stated by the National Institute of Health that there were around 948 deaths observed during the year 2017 due to non-melanoma skin cancer in Japan. Similarly, Australia is also facing the burden of non-melanoma skin cancer deaths. Cancer Council has stated that around 679 deaths were noted during the year 2016-2027 due to this cancer in Australia.

Above mentioned statistics indicate that non-melanoma skin cancer is showing considerable mortality across the major countries in the globe which in turn is augmenting the demand for better treatment.

North America dominates the market and expected to do Same in the Forecast Period

North America is expected to dominate the market in the forecast period. As per the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma, the deadliest kind of skin cancer, are caused by exposure to ultraviolet (UV) light. It is estimated that approximately 9,500 people in the United States are diagnosed with skin cancer every day. Thus, the increasing incidences of skin cancer in the region is a major factor driving the growth of the market studied. Additionally, the recent advancements of skin cancer therapy, including photodynamic therapy (PDT), have been widely used in treating non-melanoma skin malignancies, thus boosting the growth of the market studied during the forecast period.

Competitive Landscape

The global skin cancer diagnostics and therapeutics market is highly competitive and consists of a number of major players. Companies, like Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., among others, hold the substantial market share in the skin cancer therapeutics market.

Key Topics Covered





4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Incidence of Skin Cancer

4.2.2 Rising Awareness About Skin Cancer

4.2.3 Extensive R&D Pipelines

4.3 Market Restraints

4.3.1 High Cost Associated with Therapy

4.3.2 Stringent Regulatory Environment

4.4 Porter's Five Force Analysis


5.1 By Disease Type

5.1.1 Melanoma

5.1.2 Non-melanoma

5.2 By Diagnosis

5.2.1 Dermatoscopy

5.2.2 Skin Biopsy

5.2.3 Lymph Node Biopsy

5.2.4 Imaging Tests

5.2.5 Blood Tests

5.2.6 Others

5.3 By Treatment

5.3.1 Chemotherapy

5.3.2 Photodynamic Therapy

5.3.3 Immunotherapy

5.3.4 Targeted Therapy

5.3.5 Surgery

5.3.6 Radiation Therapy

5.3.7 Others

5.4 Geography

5.4.1 North America US Canada Mexico

5.4.2 Europe Germany UK France Italy Spain Rest of Europe

5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific

5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa

5.4.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles

6.1.1 Abbott Inc.

6.1.2 Amgen Inc.

6.1.3 AstraZeneca PLC

6.1.4 Bristol-Myers Squibb Company

6.1.5 F. Hoffmann-La Roche Ltd.

6.1.6 GlaxoSmithKline PLC

6.1.7 Merck & Co. Inc.

6.1.8 Novartis AG

6.1.9 Qiagen N.V.

6.1.10 Sun Pharmaceutical Industries Ltd.


For more information about this report visit https://www.researchandmarkets.com/r/lzspug


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900